Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2006-10-31
2006-10-31
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S190100, C424S234100, C424S251100
Reexamination Certificate
active
07128910
ABSTRACT:
The invention discloses theMoraxella catarrhalisouter membrane protein-106 (OMP106) polypeptide, polypeptides derived therefrom (OMP106-derived polypeptides), nucleotide sequences encoding OMP106 polypeptides, and antibodies that specifically bind the OMP106 polypeptide and/or OMP106-derived polypeptides. Also disclosed are immunogenic, prophylactic or therapeutic compositions, including vaccines, comprising OMP106 polypeptide and/or OMP106-derived polypeptides. The invention additionally discloses methods of inducing immune responses toM. catarrhalisandM. catarrhalisOMP106 polypeptides and OMP106-derived polypeptides in animals.
REFERENCES:
patent: 5607846 (1997-03-01), Murphy et al.
patent: 5808024 (1998-09-01), Sasaki et al.
patent: 6335018 (2002-01-01), Sasaki et al.
patent: 6440424 (2002-08-01), Sasaki et al.
patent: 6440425 (2002-08-01), Sasaki et al.
patent: 6706269 (2004-03-01), Ruelle et al.
patent: 6764834 (2004-07-01), Ruelle
patent: WO 93/03761 (1993-04-01), None
patent: WO 96/34960 (1996-11-01), None
Sequence alignment for SEQ ID No. 10.
Kyd, et al. , Vaccine , vol. 18, pp. 398-406 ,2000.
Chen et al. Infection and Immunity, vol. 64, No. 6, pp. 1900-1905, 1996.
Gu, et al. Infection and Immunity, vol. 66, No. 5, pp. 1891-1897, May 1998.
Hu et al. Infection and Immunity vol. 68, No. 9, pp. 4980-4985, 2000.
Samukawa et al. JID, vol. 181, pp. 1842-1845, 2000.
Aebi et al., 1997,Infection&Immunity65:4367-4377.
Bartos & Murphy, 1988,J. Infect. Dis.158:761-765.
Bogosian et al., 1993,Gene, 137:17-22.
Helminen et al., 1993,Infect. Immun.61:2003-2010.
Helminen et al., 1994,J. Infect. Dis.170:867-872.
Kellens et al., 1995,Infection23:37-41.
Klingman & Murphy, 1994,Infect. Immun.62:1150-1155.
Kyd et al., 1988,Outer-membrane antigen expression by Moraxella(Branhamella)catarrhalis influences pulmonary clearance, J. Med. Microbiol., 47:159-168.
Mbaki et al., 1987,Tohuku J. Exp. Med.153:111-121.
Murphy & Bartos, 1989,Infect. Immun.57:2938-2941.
Murphy & Loeb, 1989,,Microbial Pathogen6:159-174.
Murphy et al., 1990,Amer. J. Med.88 (5A):41S-45S.
Murphy et al., 1993,Molecul. Microbiol.10:87-97.
Poolman J., 1999,Handb. Exp. Pharmacol.133 (Vaccines) 235-248.
Rikitomi et al., 1991,Scand. J. Infect. Dis.23:559-567.
Sarwar et al., 1992,Infect. Immun.60:804-809.
Sasaki et al., 1996,Abstract of the 96thGen Mtg of the Amer. soc for Microbiol.,May 19-27, 1996, B-181.
Soto-Hernandez et al., 1989,J. Clin. Microbiol.27:903-908.
Tucker et al., 1994,Annual Meeting of Amer. Soc. Microbiol.Abstr. D124.
Verduin et al., 1995Abstr. of the 95th Gen. Mtg. of the Amer. Soc. for Microbiol.p. 189 Abstr. B-137.
Unhanand et al., 1992,J. Infect. Dis.165:644-650.
Cain, T. J., et al, 1994, Solubilization of glycosyl-phosphatidylinositol-anchored proteins in guiescent and stimulated neutrophils, Biochim Biophys Acta., 1235(1):69-78.
Nebl, T., et al, 2002, Proteomic analysis of a detergent-resistant membrane skeleton from neutrophil plasma membranes, J. Bio Chem, 227 (45):43399-43409.
Corradin, G., 1990, Antigen processing and presentation, Immunol Lett, 25(1-3):11-13.
Beck-Sickinger, A.G., et al, 1993, Epitope mapping: synthetic approaches to the understanding of molecular recognition in the immune system, Pharm Acta Helv., 68(1):3-20.
Lane, D.P., et al, 1993, Epitope mapping using bacteriophage peptide libraries, Curr Opin Immunol., 5(2):268-71.
Sethl, S., et al, Antigenic heterogeneity and molecular analysis of CopB ofMoraxella(Brunhamella)catarrhalis. Infection and Immunity (1997) 65(9):3666.
Hays, J., et al, Total genome polymorphism and low frequency of intra-genomic variation in uspA1 and uspA2 genes ofMoraxella catarrhalisin otitis prone and non-prone children up to two years of age. Vaccine (2003), 21:1118.
Vretou, E., et al, Identification of protective epitopes by sequencing of the Major Outer Membrane Protein gene of a variant strain ofChlamydia psittaciserotype 1. Infection and Immunity (2001) 69(1):607.
Westbay, T.D., et al, Dissociation of immune determinants of Outer Membrane Proteins ofChlamydia psittacistrain guinea pig inclusion conjunctivitis. Infection and Immunity (1994) 62(12):5614.
Brunham, R., et al,Chlamydria trachomatisantigens: role in Immunity and pathogenesis. Infectious Agents and Disease (1994) 3(5):218.
Zhang, Y., et al, Comparison of the Major Outer Membrane Protein (MOMP) gene of mouse penumonitis (MoPn) and hamster SFPD strains ofChlamydia trachomatiswith other Chlamydia strains. Mo. Biol. Evol. (1993), 10(6):1327.
Plosila Laura
Tucker Kenneth
Emergent Product Development Gaithersburg Inc.
Foley & Lardner LLP
Navarro Mark
Talapatra Sunit
Villacorta Gilberto M.
LandOfFree
Moraxella catarrahalis outer membrane protein-106... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Moraxella catarrahalis outer membrane protein-106..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Moraxella catarrahalis outer membrane protein-106... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716599